<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02558829</url>
  </required_header>
  <id_info>
    <org_study_id>AEZS-130-052</org_study_id>
    <secondary_id>2015-002337-22</secondary_id>
    <nct_id>NCT02558829</nct_id>
  </id_info>
  <brief_title>Validation of Macimorelin as a Test for Adult Growth Hormone Deficiency</brief_title>
  <official_title>Confirmatory Validation of Oral Macimorelin as a Growth Hormone (GH) Stimulation Test (ST) for the Diagnosis of Adult Growth Hormone Deficiency (AGHD) in Comparison With the Insulin Tolerance Test (ITT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AEterna Zentaris</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AEterna Zentaris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Macimorelin Growth Hormone Stimulation Test (GHST) will be compared with the Insulin
      Tolerance Test (ITT) in an open-label, randomized, 2-way crossover Trial. The trial will
      include subjects suspected to have adult growth hormone deficiency (AGHD) and a group of
      healthy control subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Trial subjects will be assigned to groups of descending likelihood of having AGHD:

      Group A, B, C: High, intermediate, and low likelihood of GHD, respectively; Group D: Healthy
      control subjects matching Group A subjects .

      The sequential order of the GHSTs for suspected AGHD subjects (Group A-C) will be determined
      by stratified randomization; healthy control subjects (Group D) will be tested in the same
      sequence as the matched Group A subjects.

      Serum concentrations of GH will be measured at pre-defined time points before and after GHST
      with macimorelin or insulin. A peak GH value below the GHST-specific cut-off value will be
      considered 'test positive'. The ITT will be considered as comparator (non-reference standard)
      to assess positive and negative agreement of both GHSTs, based on the predefined cut-off
      values.

      The following cut-off values for simulated GH levels were used for both GHST tests to be
      compared: macimorelin-GHST: GH: 2.8 ng/mL, ITT: GH: 5.1 ng/mL.

      Amendment no. 1 (repeatability extension): had been issued for selected sites in Europe to
      obtain exploratory data on the repeatability of the MAC in a subset of subjects (planned
      N=30, 10 per Group) that had completed the core study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 3, 2015</start_date>
  <completion_date type="Actual">November 29, 2016</completion_date>
  <primary_completion_date type="Actual">November 29, 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>This was an open label trial. No masking with regard to the Growth Hormone Stimulation Tests (GHSTs) performed was done. However, Data Review Committee/Sponsor/Project Management was masked towards the Growth Hormone (GH) values as results fo both tests. GH values were provided to the investigator only after both GHSTs had been performed, to avoid bias.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Co-primary Efficacy Variables: Percent Positive and Percent Negative Agreement of Macimorelin-GHST (MAC) With ITT</measure>
    <time_frame>90 minutes</time_frame>
    <description>In the primary efficacy analysis, the estimated percentages of the agreements and the two-sided 95% confidence interval (or one-sided 97.5% confidence interval) of the percent agreement based on Clopper-Pearson are presented. The probability for a &quot;Negative Agreement&quot; equals the sum of the probability of both tests being correct (negative test results for both tests for subjects with &quot;true non-AGHD&quot;) and the probability of both tests being wrong (negative test results for both tests for subjects with &quot;true AGHD&quot;).
The performance of the GHST with Macimorelin was considered to be acceptable if the lower bound of the two-sided 95% confidence interval (or lower bound of the one-sided 97.5% confidence interval) for the primary efficacy variables was 75% or higher for 'percent negative agreement', and 70% or higher for the 'percent positive agreement'.
The following cut-off values for stimulated GH levels were used: - MAC: GH: 2.8 ng/mL, - ITT: GH: 5.1 ng/mL.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Agreements (Positive/ Negative) for MAC and ITT</measure>
    <time_frame>90 minutes</time_frame>
    <description>As part of the secondary efficacy analysis, the percent of overall agreement was analyzed, using the same methodology described for the analyses for the primary efficacy variables.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Any Test Emergent Adverse Event (TEAE), With Any TEAE Likely or Possibly Related, and With Any Test Emergent Severe AE</measure>
    <time_frame>up to 70 days</time_frame>
    <description>GHST ('Test') emergent AEs (TEAEs): AEs occurring or observed from the day of first GHST (administration of an IMP) throughout End-of-Study (EOS) visit or Early Termination, whichever occurred first. TEAEs were analyzed and compared for both GHSTs. Detailed listings are presented in the Adverse Events section. The frequencies presented in this section refer to number of subjects with any TEAE, each subject was counted only once within each category.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ECG: Change in Heart Rate From Baseline at 60 Minutes Post-dose</measure>
    <time_frame>60 minutes</time_frame>
    <description>During the GHSTs, ECGs were measured at pre-dose (up to 15 min before) and 60 minutes post-dose. Furthermore, ECGs were measured at screening and at End-of-Study (EOS) Visit.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Sensitivity and Specificity of the MAC, GH: 2.8 ng/mL</measure>
    <time_frame>90 minutes</time_frame>
    <description>Exploratory evaluation of sensitivity and specificity of the MAC as performance characteristic, based on test outcome in Group A and Group D subjects.</description>
  </other_outcome>
  <other_outcome>
    <measure>Agreement (Positive/Negative) for MAC Core Study Part and MAC Repeatability Extension (Amendment 1)</measure>
    <time_frame>90 minutes</time_frame>
    <description>Amendment no 1 (repeatability extension) had been issued for selected sites in Europe to obtain exploratory data on the repeatability of the MAC in a subset of subjects that had completed the core study. Pre-defined MAC cut-off point GH: 2.8 ng/mL. Agreements were calculated with two-sided 95% confidence intervals.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">157</enrollment>
  <condition>Growth Hormone Deficiency With Pituitary Anomalies</condition>
  <arm_group>
    <arm_group_label>GHST Sequence A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1st Macimorelin-GHST, 2nd Insulin Tolerance Test</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GHST Sequence B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1st Insulin Tolerance Test, 2nd Macimorelin-GHST</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Macimorelin</intervention_name>
    <description>macimorelin acetate, 0.5 mg/kg body weight, drinking solution, single dose</description>
    <arm_group_label>GHST Sequence A</arm_group_label>
    <arm_group_label>GHST Sequence B</arm_group_label>
    <other_name>Macimorelin-GHST (MAC)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin</intervention_name>
    <description>Insulin, 0.10 U/kg (0.15 U/kg if BMI &gt; 30 kg/m2), intravenous injection, single dose</description>
    <arm_group_label>GHST Sequence A</arm_group_label>
    <arm_group_label>GHST Sequence B</arm_group_label>
    <other_name>Insulin Tolerance Test (ITT)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Suspected growth hormone deficiency (GHD), based on either of the following:

               -  structural hypothalamic or pituitary disease, or

               -  surgery or irradiation in these areas, or

               -  head trauma as an adult, or

               -  evidence of other pituitary hormone deficiencies, or

               -  idiopathic childhood onset GHD (without known hypothalamic or pituitary lesion or
                  injury).

          -  Healthy* control subjects, matching a 'high likelihood GHD' subjects

        Exclusion Criteria:

          -  GH therapy within 1 month prior to anticipated first GHST within this trial (within 3
             months in case of long-acting GH formulation).

          -  GHST within 7 days prior to the anticipated first test day within the trial.

          -  Subjects with a medical history and clinical signs of a not adequately treated thyroid
             dysfunction or subjects who had a change in thyroid therapy within 30 days prior to
             anticipated first test day within the trial.

          -  Untreated hypogonadism or not on a stable substitution treatment within 30 days prior
             to anticipated first test day within the trial.

          -  Treatment with drugs directly affecting the pituitary secretion of somatotropin (e.g.
             somatostatin analogues, clonidine, levodopa, and dopamine agonists) or provoking the
             release of somatostatin; antimuscarinic agents (atropine).

          -  Concomitant use of a CYP3A4 inducer (e.g., carbamazepine, phenobarbital, phenytoin,
             pioglitazone, rifabutin, rifampin, St. John's Wort).

          -  Medical history of ongoing clinically symptomatic severe psychiatric disorders.

          -  Parkinson's disease.

          -  Cushing disease or patients on supraphysiologic glucocorticoid therapy within 30 days
             prior to the anticipated first test day within the trial.

          -  Type 1 diabetes or untreated or poorly controlled Type 2 diabetes, as defined by HbA1c
             &gt; 8%.

          -  Body mass index (BMI) ≥ 40.0 kg/m2.

          -  Participation in a trial with any investigational drug within 30 days prior to trial
             entry.

          -  Vigorous physical exercise within 24 hours prior to each GHST within this trial.

          -  Known hypersensitivity to macimorelin or insulin, or any of the constituents of either
             preparation.

          -  Clinically significant cardiovascular or cerebrovascular disease.

          -  Prolonged ECG QT interval, defined as corrected QT interval (QTc) &gt; 500 msec.

          -  Concomitant treatment with any drugs that might prolong QT/QTc.

          -  Elevation of laboratory parameters indicating hepatic or renal dysfunction or damage
             (aspartate amino transferase (ASAT), alanine aminotransferase (ALAT), gamma-glutamyl
             transpeptidase (GGT)&gt; 2.5 x ULN; ), creatinine, or bilirubin &gt; 1.5x ULN).

          -  Medical history of seizure disorders.

          -  Known immunosuppression.

          -  Current active malignancy other than non-melanoma skin cancer.

          -  Breastfeeding or positive urine pregnancy test (for women of childbearing potential
             only).

          -  Women of childbearing age without contraception, such as hormonal contraception or use
             of condom and spermicides or use of diaphragm and spermicides or Intra Uterine Device
             (IUD).

          -  Lack of ability or willingness to give informed consent.

          -  Anticipated non-availability for trial visits/procedures.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jose M Garcia, MD PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Baylor College of Medicine, Houston, TX, U.S.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Harbor UCLA Medical Center</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90509</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Diabetes and Endocrinology</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78731</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine-Endocrinology</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VA Puget Sound Health Care System</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Swedish Medical Center - Cherry Hill</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krankenanstalt Rudolfstiftung</name>
      <address>
        <city>Vienna</city>
        <zip>1030</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University &amp; General Hospital of Vienna, AKH,</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Lyon HCL-GH Est</name>
      <address>
        <city>Bron Cedex</city>
        <zip>69677</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GHU Paris-Sud - Hôpital de Bicêtre</name>
      <address>
        <city>Le Kremlin-Bicêtre</city>
        <zip>94270</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Haut-Lévêque</name>
      <address>
        <city>Pessac</city>
        <zip>33600</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der LMU München</name>
      <address>
        <city>Muenchen</city>
        <state>Bayern</state>
        <zip>80336</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Max Planck Institut</name>
      <address>
        <city>Muenchen</city>
        <state>Bayern</state>
        <zip>80804</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Marburg</name>
      <address>
        <city>Marburg</city>
        <state>Hessen</state>
        <zip>35033</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RWTH Aachen University Hospital</name>
      <address>
        <city>Aachen</city>
        <state>Nordrhein-Westfalen</state>
        <zip>52074</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik für Endokrinologie, Diabetes und Ernährungsmedizin der Charité</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Luca Hospital</name>
      <address>
        <city>Milano</city>
        <zip>20149</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Kliniczno-Badawcze</name>
      <address>
        <city>Elblag</city>
        <zip>82-300</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Medyczne Angelius Provita</name>
      <address>
        <city>Katowice</city>
        <zip>40-611</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Phase I - MTZ Clinical Research Sp. z o.o.</name>
      <address>
        <city>Warszawa</city>
        <zip>02-106</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wromedica</name>
      <address>
        <city>Wrocław</city>
        <zip>51-685</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Centre of Serbia</name>
      <address>
        <city>Belgrad</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Centre of Vojvodina</name>
      <address>
        <city>Novi Sad</city>
        <zip>21000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>08026</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall d' Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Conxo</name>
      <address>
        <city>Santiago de Compostela</city>
        <zip>15706</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Bartholomew's Hospital</name>
      <address>
        <city>London</city>
        <zip>EC1A 7BE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Christie NHS Foundation Trust</name>
      <address>
        <city>Manchester</city>
        <zip>M20 4BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Poland</country>
    <country>Serbia</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 21, 2015</study_first_submitted>
  <study_first_submitted_qc>September 22, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 24, 2015</study_first_posted>
  <results_first_submitted>November 27, 2017</results_first_submitted>
  <results_first_submitted_qc>January 11, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">February 9, 2018</results_first_posted>
  <last_update_submitted>March 13, 2018</last_update_submitted>
  <last_update_submitted_qc>March 13, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Adult Growth Hormone Deficiency</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endocrine System Diseases</mesh_term>
    <mesh_term>Dwarfism, Pituitary</mesh_term>
    <mesh_term>Septo-Optic Dysplasia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Hormones</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Study centers: 30 sites in 9 countries had been initiated,i.e. 25 sites in Europe (Austria, Germany, Spain, France, Italy, Poland, Serbia, and UK) with 21 of them becoming active, and 5 sites in the USA.
Study period: first subject screened: 01-Oct-2015, first subject randomized (= enrolled): 03-Dec-2015, Last subject completed: 29-Nov-2016.</recruitment_details>
      <pre_assignment_details>A subject registered in the eCRF as ‘eligible’ was assigned to the applicable Group A/B/C (= stratum). The sequence for performance of both growth hormone stimulation tests (GHSTs) in Group A/B/C subjects was assigned by stratified randomization. Healthy control subjects (Group D) were tested in the same sequence as the matched Group A subjects.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Group A Test Sequence MAC-ITT</title>
          <description>Group A: High likelihood of GHD:
structural hypothalamic or pituitary lesions and low IGF-1, and/or - three or more pituitary hormone deficiencies (PHD) and low IGF-1, or
childhood onset GHD with structural lesions and low IGF-1.
Randomization of GHST administration to following test sequence:
1st Macimorelin-GHST (MAC), 2nd Insulin Tolerance Test (ITT).
Macimorelin GHST: administration of macimorelin acetate, 0.5 mg/kg body weight, drinking solution, single dose.
Insulin Tolerance Test: administration of regular human insulin, 0.10 U/kg (0.15 U/kg if BMI &gt; 30 kg/m2), intravenous injection, single dose.</description>
        </group>
        <group group_id="P2">
          <title>Group A Test Sequence ITT-MAC</title>
          <description>Group A: High likelihood of GHD:
structural hypothalamic or pituitary lesions and low IGF-1, and/or - three or more pituitary hormone deficiencies (PHD) and low IGF-1, or
childhood onset GHD with structural lesions and low IGF-1
Randomization of GHST administration to following test sequence:
1st Insulin Tolerance Test (ITT), 2nd Macimorelin-GHST (MAC)
Insulin Tolerance Test: administration of regular human insulin, 0.10 U/kg (0.15 U/kg if BMI &gt; 30 kg/m2), intravenous injection, single dose.
Macimorelin GHST: administration of macimorelin acetate, 0.5 mg/kg body weight, drinking solution, single dose.</description>
        </group>
        <group group_id="P3">
          <title>Group B Test Sequence MAC-ITT</title>
          <description>Group B: intermediate likelihood of GHD:
- eligible subjects not qualifying for either high or low likelihood (Group A/C)
Randomization of GHST administration to following test sequence:
1st Macimorelin-GHST (MAC), 2nd Insulin Tolerance Test (ITT).
Macimorelin GHST: administration of macimorelin acetate, 0.5 mg/kg body weight, drinking solution, single dose.
Insulin Tolerance Test: administration of regular human insulin, 0.10 U/kg (0.15 U/kg if BMI &gt; 30 kg/m2), intravenous injection, single dose.</description>
        </group>
        <group group_id="P4">
          <title>Group B Test Sequence ITT- MAC</title>
          <description>Group B: intermediate likelihood of GHD:
- eligible subjects not qualifying for either high or low likelihood (Group A/C)
Randomization of GHST administration to following test sequence:
1st Insulin Tolerance Test (ITT), 2nd Macimorelin-GHST (MAC)
Insulin Tolerance Test: administration of regular human insulin, 0.10 U/kg (0.15 U/kg if BMI &gt; 30 kg/m2), intravenous injection, single dose.
Macimorelin GHST: administration of macimorelin acetate, 0.5 mg/kg body weight, drinking solution, single dose.</description>
        </group>
        <group group_id="P5">
          <title>Group C Test Sequence MAC-ITT</title>
          <description>Group C: Low likelihood of GHD
one risk factor for GHD only, such as history of distant traumatic brain injury (TBI) or one PHD only with otherwise normal pituitary function or
isolated idiopathic childhood onset GHD without additional pituitary deficits.
Randomization of GHST administration to following test sequence:
1st Macimorelin-GHST (MAC), 2nd Insulin Tolerance Test (ITT).
Macimorelin GHST: administration of macimorelin acetate, 0.5 mg/kg body weight, drinking solution, single dose.
Insulin Tolerance Test: administration of regular human insulin, 0.10 U/kg (0.15 U/kg if BMI &gt; 30 kg/m2), intravenous injection, single dose.</description>
        </group>
        <group group_id="P6">
          <title>Group C Test Sequence ITT-MAC</title>
          <description>Group C: Low likelihood of GHD
one risk factor for GHD only, such as history of distant traumatic brain injury (TBI) or one PHD only with otherwise normal pituitary function or
isolated idiopathic childhood onset GHD without additional pituitary deficits.
Randomization of GHST administration to following test sequence:
1st Insulin Tolerance Test (ITT), 2nd Macimorelin-GHST (MAC)
Insulin Tolerance Test: administration of regular human insulin, 0.10 U/kg (0.15 U/kg if BMI &gt; 30 kg/m2), intravenous injection, single dose.
Macimorelin GHST: administration of macimorelin acetate, 0.5 mg/kg body weight, drinking solution, single dose.</description>
        </group>
        <group group_id="P7">
          <title>Group D Test Sequence MAC-ITT</title>
          <description>Group D: Healthy control. Healthy subjects matching Group A subjects by sex, age, BMI, and estrogen status (females only).
Randomization of GHST administration to following test sequence:
1st Macimorelin-GHST (MAC), 2nd Insulin Tolerance Test (ITT).
Macimorelin GHST: administration of macimorelin acetate, 0.5 mg/kg body weight, drinking solution, single dose.
Insulin Tolerance Test: administration of regular human insulin, 0.10 U/kg (0.15 U/kg if BMI &gt; 30 kg/m2), intravenous injection, single dose.</description>
        </group>
        <group group_id="P8">
          <title>Group D Test Sequence ITT-MAC</title>
          <description>Group D: Healthy control. Healthy subjects matching Group A subjects by sex, age, BMI, and estrogen status (females only).
Randomization of GHST administration to following test sequence:
1st Insulin Tolerance Test (ITT), 2nd Macimorelin-GHST (MAC)
Insulin Tolerance Test: administration of regular human insulin, 0.10 U/kg (0.15 U/kg if BMI &gt; 30 kg/m2), intravenous injection, single dose.
Macimorelin GHST: administration of macimorelin acetate, 0.5 mg/kg body weight, drinking solution, single dose.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="21"/>
                <participants group_id="P3" count="24"/>
                <participants group_id="P4" count="18"/>
                <participants group_id="P5" count="18"/>
                <participants group_id="P6" count="26"/>
                <participants group_id="P7" count="18"/>
                <participants group_id="P8" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="18"/>
                <participants group_id="P3" count="21"/>
                <participants group_id="P4" count="16"/>
                <participants group_id="P5" count="16"/>
                <participants group_id="P6" count="24"/>
                <participants group_id="P7" count="17"/>
                <participants group_id="P8" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Baseline participants = safety analysis set (SAF, N=157). Efficacy analysis is based on the modified Intention-to-Treat (mITT, N=140): all randomized subjects in whom both GHSTs of the cross-over are evaluable. (In the EU only: 34 patients from the mITT underwent a repeated MAC (repeatability extension, Amendment 1).)</population>
      <group_list>
        <group group_id="B1">
          <title>Group A</title>
          <description>High likelihood of growth hormone deficiency (GHD):
Structural hypothalamic or pituitary lesions and low insulin-like growth factor 1 (IGF-1), and/or
Three or more pituitary hormone deficiencies (PHD) and low IGF-1, or
Childhood onset GHD with structural lesions and low IGF-1.</description>
        </group>
        <group group_id="B2">
          <title>Group B</title>
          <description>Intermediate likelihood of GHD:
• Eligible subjects not qualifying for either high or low likelihood (Group A/C)</description>
        </group>
        <group group_id="B3">
          <title>Group C</title>
          <description>Low likelihood of GHD:
One risk factor for GHD only, such as history of distant traumatic brain injury (TBI) or one PHD only with otherwise normal pituitary function or
Isolated idiopathic childhood onset GHD without additional pituitary deficits</description>
        </group>
        <group group_id="B4">
          <title>Group D</title>
          <description>Healthy control. Healthy subjects matching Group A subjects by sex, age, body mass index (BMI), and estrogen status (females only).</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="42"/>
            <count group_id="B2" value="42"/>
            <count group_id="B3" value="44"/>
            <count group_id="B4" value="29"/>
            <count group_id="B5" value="157"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42.3" spread="15.0"/>
                    <measurement group_id="B2" value="45.8" spread="11.8"/>
                    <measurement group_id="B3" value="34.9" spread="10.5"/>
                    <measurement group_id="B4" value="40.0" spread="12.4"/>
                    <measurement group_id="B5" value="40.7" spread="13.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="14"/>
                    <measurement group_id="B5" value="64"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="35"/>
                    <measurement group_id="B4" value="15"/>
                    <measurement group_id="B5" value="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="36"/>
                    <measurement group_id="B4" value="29"/>
                    <measurement group_id="B5" value="128"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="34"/>
                    <measurement group_id="B4" value="29"/>
                    <measurement group_id="B5" value="135"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Austria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="18"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="29"/>
                    <measurement group_id="B5" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Italy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>France</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serbia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (kg/m^2)</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27.6" spread="4.6"/>
                    <measurement group_id="B2" value="29.8" spread="4.5"/>
                    <measurement group_id="B3" value="27.9" spread="5.7"/>
                    <measurement group_id="B4" value="26.1" spread="3.2"/>
                    <measurement group_id="B5" value="28.0" spread="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Co-primary Efficacy Variables: Percent Positive and Percent Negative Agreement of Macimorelin-GHST (MAC) With ITT</title>
        <description>In the primary efficacy analysis, the estimated percentages of the agreements and the two-sided 95% confidence interval (or one-sided 97.5% confidence interval) of the percent agreement based on Clopper-Pearson are presented. The probability for a “Negative Agreement” equals the sum of the probability of both tests being correct (negative test results for both tests for subjects with “true non-AGHD”) and the probability of both tests being wrong (negative test results for both tests for subjects with “true AGHD”).
The performance of the GHST with Macimorelin was considered to be acceptable if the lower bound of the two-sided 95% confidence interval (or lower bound of the one-sided 97.5% confidence interval) for the primary efficacy variables was 75% or higher for ‘percent negative agreement’, and 70% or higher for the ‘percent positive agreement’.
The following cut-off values for stimulated GH levels were used: - MAC: GH: 2.8 ng/mL, - ITT: GH: 5.1 ng/mL.</description>
        <time_frame>90 minutes</time_frame>
        <population>All subjects from Groups A, B, C, D included in the modified intention-to-treat (mITT) analysis, N=140</population>
        <group_list>
          <group group_id="O1">
            <title>Positive MAC, Positive ITT</title>
            <description>Test outcome positive for MAC and for ITT</description>
          </group>
          <group group_id="O2">
            <title>Positive MAC, Negative ITT</title>
            <description>Test outcome positive for MAC and negative for ITT</description>
          </group>
          <group group_id="O3">
            <title>Negative MAC, Positive ITT</title>
            <description>Test outcome negative for MAC and positive for ITT</description>
          </group>
          <group group_id="O4">
            <title>Negative MAC, Negative ITT</title>
            <description>Test outcome negative for MAC and for ITT</description>
          </group>
        </group_list>
        <measure>
          <title>Co-primary Efficacy Variables: Percent Positive and Percent Negative Agreement of Macimorelin-GHST (MAC) With ITT</title>
          <description>In the primary efficacy analysis, the estimated percentages of the agreements and the two-sided 95% confidence interval (or one-sided 97.5% confidence interval) of the percent agreement based on Clopper-Pearson are presented. The probability for a “Negative Agreement” equals the sum of the probability of both tests being correct (negative test results for both tests for subjects with “true non-AGHD”) and the probability of both tests being wrong (negative test results for both tests for subjects with “true AGHD”).
The performance of the GHST with Macimorelin was considered to be acceptable if the lower bound of the two-sided 95% confidence interval (or lower bound of the one-sided 97.5% confidence interval) for the primary efficacy variables was 75% or higher for ‘percent negative agreement’, and 70% or higher for the ‘percent positive agreement’.
The following cut-off values for stimulated GH levels were used: - MAC: GH: 2.8 ng/mL, - ITT: GH: 5.1 ng/mL.</description>
          <population>All subjects from Groups A, B, C, D included in the modified intention-to-treat (mITT) analysis, N=140</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="140"/>
                <count group_id="O2" value="140"/>
                <count group_id="O3" value="140"/>
                <count group_id="O4" value="140"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="19"/>
                    <measurement group_id="O4" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The estimated percentages of the agreements and the two-sided 95% confidence interval (or one-sided 97.5% confidence interval) of the percent agreement based on Clopper-Pearson are presented. The performance of the MAC (cut-off point 2.8 ng/mL) was considered to be acceptable if the lower bound of the two-sided 95% CI (or lower bound of the one-sided 97.5% CI) was 75% or higher for ‘percent negative agreement’, and 70% or higher for the ‘percent positive agreement’.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Positive percent agreement [%] = 100% x A/(A+C). A= MAC outcome positive and ITT outcome positive; C = MAC outcome negative and ITT positive</non_inferiority_desc>
            <param_type>CI (Clopper Pearson): positive agreement</param_type>
            <param_value>74.32</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>62.84</ci_lower_limit>
            <ci_upper_limit>83.78</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Please refer to Statistical Analysis 1.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Negative percent agreement [%] = 100% x D/(B+D). D = MAC outcome negative and ITT outcome negative; B = MAC outcome positive and ITT outcome negative</non_inferiority_desc>
            <param_type>CI (Clopper Pearson): negative agreement</param_type>
            <param_value>93.94</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>85.20</ci_lower_limit>
            <ci_upper_limit>98.32</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Agreements (Positive/ Negative) for MAC and ITT</title>
        <description>As part of the secondary efficacy analysis, the percent of overall agreement was analyzed, using the same methodology described for the analyses for the primary efficacy variables.</description>
        <time_frame>90 minutes</time_frame>
        <population>All subjects from Groups A, B, C, D included in the modified intention-to-treat (mITT) analysis, N=140</population>
        <group_list>
          <group group_id="O1">
            <title>Positive MAC, Positive ITT</title>
            <description>Test outcome positive for MAC and for ITT</description>
          </group>
          <group group_id="O2">
            <title>Positive MAC, Negative ITT</title>
            <description>Test outcome positive for MAC and negative for ITT</description>
          </group>
          <group group_id="O3">
            <title>Negative MAC, Positive ITT</title>
            <description>Test outcome negative for MAC and positive for ITT</description>
          </group>
          <group group_id="O4">
            <title>Negative MAC, Negative ITT</title>
            <description>Test outcome negative for MAC and for ITT</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Agreements (Positive/ Negative) for MAC and ITT</title>
          <description>As part of the secondary efficacy analysis, the percent of overall agreement was analyzed, using the same methodology described for the analyses for the primary efficacy variables.</description>
          <population>All subjects from Groups A, B, C, D included in the modified intention-to-treat (mITT) analysis, N=140</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="140"/>
                <count group_id="O2" value="140"/>
                <count group_id="O3" value="140"/>
                <count group_id="O4" value="140"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="19"/>
                    <measurement group_id="O4" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>This variable was analyzed using the same methodology described for the analyses for the primary efficacy variables. in the below, the results for Step 1 (peak GH level among all post baseline samples) are presented.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>The secondary diagnostic accuracy measure was ‘percent overall agreement’.</non_inferiority_desc>
            <param_type>overall agreement</param_type>
            <param_value>83.57</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>76.38</ci_lower_limit>
            <ci_upper_limit>89.29</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Any Test Emergent Adverse Event (TEAE), With Any TEAE Likely or Possibly Related, and With Any Test Emergent Severe AE</title>
        <description>GHST (‘Test’) emergent AEs (TEAEs): AEs occurring or observed from the day of first GHST (administration of an IMP) throughout End-of-Study (EOS) visit or Early Termination, whichever occurred first. TEAEs were analyzed and compared for both GHSTs. Detailed listings are presented in the Adverse Events section. The frequencies presented in this section refer to number of subjects with any TEAE, each subject was counted only once within each category.</description>
        <time_frame>up to 70 days</time_frame>
        <population>All subjects of Group A, B, C, D in the safety population.</population>
        <group_list>
          <group group_id="O1">
            <title>Insulin Tolerance Test (ITT), All Groups, SAF Population</title>
            <description>All subjects of Group A, B, C, and D with at least one ITT performed: N=157</description>
          </group>
          <group group_id="O2">
            <title>Macimorelin GHST (MAC), All Groups, SAF Population</title>
            <description>All subjects of Group A, B, C, and D with at least one macimorelin GHST: N=154 (three subjects were not exposed to MAC but were exposed to ITT only).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Any Test Emergent Adverse Event (TEAE), With Any TEAE Likely or Possibly Related, and With Any Test Emergent Severe AE</title>
          <description>GHST (‘Test’) emergent AEs (TEAEs): AEs occurring or observed from the day of first GHST (administration of an IMP) throughout End-of-Study (EOS) visit or Early Termination, whichever occurred first. TEAEs were analyzed and compared for both GHSTs. Detailed listings are presented in the Adverse Events section. The frequencies presented in this section refer to number of subjects with any TEAE, each subject was counted only once within each category.</description>
          <population>All subjects of Group A, B, C, D in the safety population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="157"/>
                <count group_id="O2" value="154"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any TEAE (any relation)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="151"/>
                    <measurement group_id="O2" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any TEAE (likely or possible related)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="149"/>
                    <measurement group_id="O2" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any test emergent severe AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ECG: Change in Heart Rate From Baseline at 60 Minutes Post-dose</title>
        <description>During the GHSTs, ECGs were measured at pre-dose (up to 15 min before) and 60 minutes post-dose. Furthermore, ECGs were measured at screening and at End-of-Study (EOS) Visit.</description>
        <time_frame>60 minutes</time_frame>
        <population>All subjects of Group A, B, C, D in the safety population. Because of single ECGs missing, the number of participants analyzed here is lower than the number of the subjects in the SAF.</population>
        <group_list>
          <group group_id="O1">
            <title>MAC, Heart Rate at Pre-dose</title>
            <description>Macimorelin GHST, heart rate (HR) value at test/time point pre-dose.</description>
          </group>
          <group group_id="O2">
            <title>MAC, HR at Post-dose</title>
            <description>Macimorelin GHST, HR value at test/time point 60 minutes post-dose.</description>
          </group>
          <group group_id="O3">
            <title>ITT, HR at Pre-dose</title>
            <description>Insulin Tolerance Test, HR value at test/time point pre-dose.</description>
          </group>
          <group group_id="O4">
            <title>ITT, HR at Post-dose</title>
            <description>Insulin Tolerance Test, HR value at test/time point 60 minutes post-dose.</description>
          </group>
        </group_list>
        <measure>
          <title>ECG: Change in Heart Rate From Baseline at 60 Minutes Post-dose</title>
          <description>During the GHSTs, ECGs were measured at pre-dose (up to 15 min before) and 60 minutes post-dose. Furthermore, ECGs were measured at screening and at End-of-Study (EOS) Visit.</description>
          <population>All subjects of Group A, B, C, D in the safety population. Because of single ECGs missing, the number of participants analyzed here is lower than the number of the subjects in the SAF.</population>
          <units>beats per minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="153"/>
                <count group_id="O2" value="153"/>
                <count group_id="O3" value="156"/>
                <count group_id="O4" value="155"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.4" spread="10.35"/>
                    <measurement group_id="O2" value="60.5" spread="9.47"/>
                    <measurement group_id="O3" value="63.7" spread="10.70"/>
                    <measurement group_id="O4" value="65.6" spread="10.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Pre/post dose comparison of ECGs was done for both GHSTs. During the GHSTs, ECGs were measured at pre-dose (up to 15 min before) and 60 minutes post-dose. Furthermore, ECGs were measured at screening and at End-of-Study (EOS) Visit.
Calculations were done from two time points: baseline and 60 min post-dose. Baseline is either the screening or pre-dose value.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-2.9</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>6.38</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Please refer to Statistical Analysis 1 for this secondary outcome measure.</non_inferiority_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.8</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>8.15</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Sensitivity and Specificity of the MAC, GH: 2.8 ng/mL</title>
        <description>Exploratory evaluation of sensitivity and specificity of the MAC as performance characteristic, based on test outcome in Group A and Group D subjects.</description>
        <time_frame>90 minutes</time_frame>
        <population>All high likelihood AGHD subjects of Group A (N=38) of the mITT population as ‘true’ AGHD subjects and all healthy matching subjects of Group D (N=25) of the mITT population as ‘true’ AGHD negative subjects</population>
        <group_list>
          <group group_id="O1">
            <title>Positive MAC, Group A</title>
            <description>Positive test outcome of the MAC in subjects of AGHD likelihood group A (high likelihood)</description>
          </group>
          <group group_id="O2">
            <title>Positive MAC, Group D</title>
            <description>positive test outcome of the MAC in subjects of Group D (healthy matched controls)</description>
          </group>
          <group group_id="O3">
            <title>Negative MAC, Group A</title>
            <description>Negative test outcome of the MAC in subjects of AGHD likelihood group A (high likelihood)</description>
          </group>
          <group group_id="O4">
            <title>Negative MAC, Group D</title>
            <description>Negative test outcome of the MAC in subjects of Group D (healthy matched controls)</description>
          </group>
        </group_list>
        <measure>
          <title>Sensitivity and Specificity of the MAC, GH: 2.8 ng/mL</title>
          <description>Exploratory evaluation of sensitivity and specificity of the MAC as performance characteristic, based on test outcome in Group A and Group D subjects.</description>
          <population>All high likelihood AGHD subjects of Group A (N=38) of the mITT population as ‘true’ AGHD subjects and all healthy matching subjects of Group D (N=25) of the mITT population as ‘true’ AGHD negative subjects</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="38"/>
                <count group_id="O4" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Sensitivity was estimated for the MAC at the pre-defined cut-off point GH: 2.8 ng/mL.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Sensitivity is the probability that the test result is positive given the subject has the disease (for the purpose of this analysis, all group A subjects were assumed to have AGHD, but none of the group D subjects). Sensitivity (SS) was estimated by: SS = TP/(TP+FN). TP=True AGHD positive subject; FN=False AGHD negative subject.</non_inferiority_desc>
            <param_type>CI (Clopper Pearson)</param_type>
            <param_value>0.87</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.72</ci_lower_limit>
            <ci_upper_limit>0.96</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Specificity was estimated for the MAC at the pre-defined cut-off point GH: 2.8 ng/mL.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Specificity is the probability that the test result is negative given the subject does not have the disease.
Specificity (SP) was estimated by: SP = TN/(TN+FP). TN = True AGHD negative Subjects; FP = False AGHD positive subjects.</non_inferiority_desc>
            <param_type>CI (Clopper Pearson)</param_type>
            <param_value>0.96</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.80</ci_lower_limit>
            <ci_upper_limit>1.00</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Agreement (Positive/Negative) for MAC Core Study Part and MAC Repeatability Extension (Amendment 1)</title>
        <description>Amendment no 1 (repeatability extension) had been issued for selected sites in Europe to obtain exploratory data on the repeatability of the MAC in a subset of subjects that had completed the core study. Pre-defined MAC cut-off point GH: 2.8 ng/mL. Agreements were calculated with two-sided 95% confidence intervals.</description>
        <time_frame>90 minutes</time_frame>
        <population>All subjects included in the modified intention-to-treat (mITT) analysis who also participated in the repeatability extension, i.e. N=34 (comprising 13 Group A, 12 Group B, and 9 Group C subjects).</population>
        <group_list>
          <group group_id="O1">
            <title>Positive MAC Core, Positive MAC Repeatability</title>
            <description>Test outcome positive for MAC in core study part and positive for MAC in the repeatability extension.</description>
          </group>
          <group group_id="O2">
            <title>Positive MAC Core, Negative MAC Repeatability</title>
            <description>Test outcome positive for MAC in core study part and negative for MAC in the repeatability extension.</description>
          </group>
          <group group_id="O3">
            <title>Negative MAC Core, Negative MAC Repeatability</title>
            <description>Test outcome negative for MAC in core study part and negative for MAC in the repeatability extension.</description>
          </group>
          <group group_id="O4">
            <title>Negative MAC Core, Positive MAC Repeatability</title>
            <description>Test outcome negative for MAC in core study part and positive for MAC in the repeatability extension.</description>
          </group>
        </group_list>
        <measure>
          <title>Agreement (Positive/Negative) for MAC Core Study Part and MAC Repeatability Extension (Amendment 1)</title>
          <description>Amendment no 1 (repeatability extension) had been issued for selected sites in Europe to obtain exploratory data on the repeatability of the MAC in a subset of subjects that had completed the core study. Pre-defined MAC cut-off point GH: 2.8 ng/mL. Agreements were calculated with two-sided 95% confidence intervals.</description>
          <population>All subjects included in the modified intention-to-treat (mITT) analysis who also participated in the repeatability extension, i.e. N=34 (comprising 13 Group A, 12 Group B, and 9 Group C subjects).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="34"/>
                <count group_id="O3" value="34"/>
                <count group_id="O4" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="16"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Please refer to Statistical Analysis 1 for this outcome.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Positive percent agreement [%] = 100% x A/(A+C). A= test outcome positive for MAC core study part and positive for MAC repeatability extension; C = test outcome positive for MAC core study part and negative for MAC repeatability extension.</non_inferiority_desc>
            <param_type>CI (Clopper Pearson): positive agreement</param_type>
            <param_value>88.89</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>65.29</ci_lower_limit>
            <ci_upper_limit>98.62</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Amendment no 1 had been issued for selected sites in Europe to obtain exploratory data on the repeatability of the MAC in a subset of subjects that had completed the core study.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Negative percent agreement [%] = 100% x D/(B+D). D = test outcome negative for MAC core study part and negative for MAC repeatability extension; B = test outcome negative for MAC core study part and positive for MAC repeatability extension</non_inferiority_desc>
            <param_type>CI (Clopper Pearson): negative agreement</param_type>
            <param_value>100.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>79.41</ci_lower_limit>
            <ci_upper_limit>100.00</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Throughout the trial, i.e. over a period of ca. 15 months, the subjects were questioned and/or examined by the Investigators or his/her designee for evidence of adverse events (AEs). Per subject, the time frame for collection of such data was up to 70 days.</time_frame>
      <desc>GHST emergent adverse events (TEAEs): all untoward effects during or after a GHST were documented in the electronic Case Report Form (eCRF), to ensure balanced representation of both GHSTs. Safety analyses were conducted using data from the Safety Population (SAF). The number and percentage of subjects with TEAEs was displayed for each GHST test drug by SOC and preferred term. Additionally, TEAEs were tabulated for each GHST by severity and by relationship to the GHST test drug.</desc>
      <group_list>
        <group group_id="E1">
          <title>Macimorelin GHST (MAC), SAF Population</title>
          <description>Macimorelin GHST (MAC): combined safety data from core study and repeatability extension (Amendment 1, European sites only)).
All subjects of Group A, B, C, D with at least one macimorelin GHST performed: N=154.
All subjects of Group A, B, C, D valid for safety (SAF) analysis: N=157. (three subjects were exposed to the ITT only).
Repeatability extension (planned repetition of the MAC): subjects of Group A, B, C valid for safety (SAF)analysis: N=34.</description>
        </group>
        <group group_id="E2">
          <title>Insulin Tolerance Test (ITT), SAF Population</title>
          <description>Insulin Tolerance Test (ITT) All subjects of Group A, B, C, D with at least one ITT performed: N=157. All subjects of Group A, B, C, D valid for safety (SAF) analysis: N=157.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 18.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="157"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="157"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Upper limp fracture</sub_title>
                <description>The patient had underwent an ITT on July 5 and the macimorelin GHST on July 12, 2016. On July 13, the patient fell of a ladder accidentally and broke his left arm. Causality reported by investigator: unrelated to study treatment.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="157"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA (18.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="151" subjects_at_risk="157"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E2" events="18" subjects_affected="17" subjects_at_risk="157"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="154"/>
                <counts group_id="E2" events="22" subjects_affected="21" subjects_at_risk="157"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="154"/>
                <counts group_id="E2" events="49" subjects_affected="43" subjects_at_risk="157"/>
              </event>
              <event>
                <sub_title>Hunger</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="154"/>
                <counts group_id="E2" events="51" subjects_affected="46" subjects_at_risk="157"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E2" events="32" subjects_affected="30" subjects_at_risk="157"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E2" events="12" subjects_affected="9" subjects_at_risk="157"/>
              </event>
              <event>
                <sub_title>Feeling cold</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="157"/>
              </event>
              <event>
                <sub_title>Feeling hot</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="154"/>
                <counts group_id="E2" events="50" subjects_affected="44" subjects_at_risk="157"/>
              </event>
              <event>
                <sub_title>Thirst</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E2" events="13" subjects_affected="12" subjects_at_risk="157"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="154"/>
                <counts group_id="E2" events="48" subjects_affected="43" subjects_at_risk="157"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="154"/>
                <counts group_id="E2" events="7" subjects_affected="5" subjects_at_risk="157"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="154"/>
                <counts group_id="E2" events="16" subjects_affected="15" subjects_at_risk="157"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E2" events="62" subjects_affected="57" subjects_at_risk="157"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E2" events="28" subjects_affected="25" subjects_at_risk="157"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="154"/>
                <counts group_id="E2" events="120" subjects_affected="105" subjects_at_risk="157"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>INSTITUTIONS / INVESTIGATORS are allowed to publish data pursuant to the Sponsor’s publication policies per individual agreements. Any material prepared for publication shall be submitted to the Sponsor for review and comment within an individually agreed period (30 up to 180 days). INSTITUTION / INVESTIGATOR shall modify the publication / presentation according to the comments by the Sponsor, provided that the scientific neutrality of the publication is not impaired hereby.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Nicola Ammer</name_or_title>
      <organization>Aeterna Zentaris</organization>
      <phone>+496942602 ext 3472</phone>
      <email>nammer@aezsinc.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

